1
|
Kuboi T, Tajika T, Endo F, Goto W, Nakajima I, Hasegawa S, Nakajima D, Hasokawa T, Chikuda H. Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease. Prog Rehabil Med 2021; 6:20210023. [PMID: 34056142 PMCID: PMC8149854 DOI: 10.2490/prm.20210023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 05/12/2021] [Indexed: 11/29/2022] Open
Abstract
Objectives: This study was conducted to investigate the changes in clinical and psychosocial outcomes in patients with Dupuytren’s disease after initial treatment with collagenase Clostridium histolyticum (CCH) injection. Methods: This study involved 14 patients with Dupuytren’s disease who underwent treatment with CCH injection. The range of motion of each phalangeal joint was measured before treatment and at 6 months posttreatment. The following assessments were also carried out pre- and posttreatment: the Geriatric Depression Scale Short – Japanese version (GDS-J) to evaluate depressive status, Hand 10 to assess hand health status, and EuroQol-5-dimension-3-level Japanese version to evaluate health-related quality of life Results: Significant improvements were found in metacarpophalangeal joint extension and proximal interphalangeal joint extension. Significant differences were also found between values before the initiation of CCH injection and those at 6 months posttreatment for the EuroQol index score and the EuroQol Visual Analog Scale (VAS). Significant positive correlations were found between the pre- to posttreatment change in GDS-J scores and for the change in Hand 10 scores. Moreover, a significant negative correlation was found between the change in GDS-J scores and change in EuroQol index scores/EuroQol VAS scores before and at 6 months after CCH injection. Conclusions: For patients with Dupuytren’s disease, CCH therapy directly improved the health-related quality of life. The degree of improvement of depressive status was associated with the degree of improvement of hand health status and health-related quality of life.
Collapse
Affiliation(s)
- Takuro Kuboi
- Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Tsuyoshi Tajika
- Department of Rehabilitation, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Fumitaka Endo
- Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Wataru Goto
- Department of Orthopaedic Surgery, Saiseikai Maebashi Hospital, Maebashi, Japan
| | - Ichiro Nakajima
- Department of Orthopaedic Surgery, Saiseikai Maebashi Hospital, Maebashi, Japan
| | - Satoshi Hasegawa
- Department of Orthopaedic Surgery, Saiseikai Maebashi Hospital, Maebashi, Japan
| | - Daisuke Nakajima
- Department of Orthopaedic Surgery, Fujioka General Hospital, Fujioka, Japan
| | - Takafumi Hasokawa
- Department of Orthopaedic Surgery, Tone Central Hospital, Numata, Japan
| | - Hirotaka Chikuda
- Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
| |
Collapse
|
2
|
Kaneshiro S, Ebina K, Hirao M, Tsuboi H, Nishikawa M, Nampei A, Nagayama Y, Takahi K, Noguchi T, Owaki H, Hashimoto J, Yoshikawa H. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab. Mod Rheumatol 2016; 27:42-49. [DOI: 10.1080/14397595.2016.1181315] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Shoichi Kaneshiro
- Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan,
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,
- Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan,
| | - Kosuke Ebina
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,
| | - Makoto Hirao
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,
| | - Hideki Tsuboi
- Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan,
| | - Masataka Nishikawa
- Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan,
| | - Akihide Nampei
- Department of Orthopaedic Surgery, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan,
| | - Yoshio Nagayama
- Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan,
| | - Koichiro Takahi
- Department of Orthopaedic Surgery, Toneyama National Hospital, Osaka, Japan, and
| | - Takaaki Noguchi
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,
| | - Hajime Owaki
- Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan,
| | - Jun Hashimoto
- Department of Rheumatology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan
| | - Hideki Yoshikawa
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,
| |
Collapse
|
3
|
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatol Int 2015; 35:1707-16. [PMID: 25991396 DOI: 10.1007/s00296-015-3283-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 05/07/2015] [Indexed: 10/23/2022]
Abstract
This observational retrospective study examined whether abatacept efficacy could be augmented with concomitant methotrexate (MTX) or tacrolimus (TAC) in patients with rheumatoid arthritis (RA) who experienced failure with prior biological disease-modifying antirheumatic drugs (DMARDs) and in whom favorable therapeutic efficacy is difficult to achieve. All patients with a prior biological DMARD history who were treated with abatacept for 52 weeks and registered in a Japanese multicentre registry were included. Clinical efficacy and safety of abatacept according to the concomitant drug used, i.e., none (ABT-mono), MTX (ABT-MTX), and TAC (ABT-TAC), were compared. A greater mean percent change of DAS28-ESR was observed in the ABT-TAC group compared with the ABT-mono group at weeks 12 (-20.5 vs. -5.4 %, p = 0.035) and 24 (-25.0 vs. -11.0 %, p = 0.036). ABT-MTX and ABT-TAC groups had a significantly higher proportion of patients who achieved low disease activity (LDA) within 52 weeks compared with the respective baselines, while no significant change was observed in the ABT-mono group. A higher proportion of patients in the ABT-TAC group achieved EULAR moderate response compared with the ABT-mono group at week 52 (66.7 vs. 35.0 %, p = 0.025). Multivariate logistic regression analysis revealed that concomitant TAC use was independently associated with the achievement of LDA and EULAR response at 52 weeks, while concomitant MTX use was not. Concomitant TAC use may offer a suitable option for RA patients treated with abatacept after prior biological DMARD failure, likely because both abatacept and TAC affect T cell activation.
Collapse
|